ArticleActa pharmacologica Sinica2021
Lipid/PAA-coated mesoporous silica nanoparticles for dual-pH-responsive codelivery of arsenic trioxide/paclitaxel against breast cancer cells.
Article in Acta pharmacologica Sinica, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 1 synthesis or guideline pooled it, 42 citations in OpenAlex.
- Breast Cancer and Arsenic Anticancer Effects: Systematic Review of the Experimental Data fromBioMed research international · 2022Pooled it
- Stimuli-responsive bioengineered platforms for precision cancer therapy.Frontiers in bioengineering and biotechnology · 2026Review
- Emerging Nanozyme Strategies for Precision Breast Cancer Treatment.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Review
- Folic Acid-Chitosan Conjugated Mesoporous Silica Nanoparticles for Enhanced Piceatannol Uptake in MCF‑7 Breast Cancer Cells.ACS omega · 2025Article
- Stimuli-Responsive Colloidal Gate for Active Modulation of Fluid Flow in Packed Beds.Langmuir : the ACS journal of surfaces and colloids · 2025Article
- Precision nanomedicine: navigating the tumor microenvironment for enhanced cancer immunotherapy and targeted drug delivery.Molecular cancer · 2025Review
- Application of responsive nano-drug carriers in bone tumor chemotherapy.Journal of bone oncology · 2025Review
- For and against tumor microenvironment: Nanoparticle-based strategies for active cancer therapy.Materials today. Bio · 2025Review
- Lipid-Coated Mesoporous Silica Particles for pH-Sensitive Tumor-Targeted Paclitaxel: Development, Characterization.Journal of Cancer · 2025Article
- Mesoporous silica nanoparticles--based functional platforms for breast cancer therapy: technological advancements.Frontiers in chemistry · 2025Review
- Innovative applications of silicon dioxide nanoparticles for targeted liver cancer treatment.Frontiers in bioengineering and biotechnology · 2025Review
- Engineering mesoporous bioactive glasses for emerging stimuli-responsive drug delivery and theranostic applications.Bioactive materials · 2024Review
- Advanced hybrid silica nanoparticles with pH-responsive diblock copolymer brushes: optimized design for controlled doxorubicin loading and release in cancer therapy.RSC advances · 2024Article
- Arsenic trioxide: applications, mechanisms of action, toxicity and rescue strategies to date.Archives of pharmacal research · 2024Review
- Current Principles, Challenges, and New Metrics in pH-Responsive Drug Delivery Systems for Systemic Cancer Therapy.Pharmaceutics · 2023Review
- Recent Advances in Mesoporous Silica Nanoparticle-Mediated Drug Delivery for Breast Cancer Treatment.Pharmaceutics · 2023Review
- Mesoporous silicas in materials engineering: Nanodevices for bionanotechnologies.Materials today. Bio · 2022Review
- Cooperative coordination-mediated multi-component self-assembly of "all-in-one" nanospike theranostic nano-platform for MRI-guided synergistic therapy against breast cancer.Acta pharmaceutica Sinica. B · 2022Article
- Inorganic Nanoparticles in Bone Healing Applications.Pharmaceutics · 2022Review
- Current Advances of Nanomedicines Delivering Arsenic Trioxide for Enhanced Tumor Therapy.Pharmaceutics · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Nanomedicine has attracted increasing attention and emerged as a safer and more effective modality in cancer treatment than conventional chemotherapy. In particular, the distinction of tumor microenvironment and normal tissues is often used in stimulus-responsive drug delivery systems for controlled release of therapeutic agents at target sites. In this study, we developed mesoporous silica nanoparticles (MSNs) coated with polyacrylic acid (PAA), and pH-sensitive lipid (PSL) for synergistic delivery and dual-pH-responsive sequential release of arsenic trioxide (ATO) and paclitaxel (PTX) (PL-PMSN-PTX/ATO). Tumor-targeting peptide F56 was used to modify MSNs, which conferred a target-specific delivery to cancer and endothelial cells under neoangiogenesis. PAA- and PSL-coated nanoparticles were characterized by TGA, TEM, FT-IR, and DLS. The drug-loaded nanoparticles displayed a dual-pH-responsive (pH
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.